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Aim
The risk of HPV-related cancers is higher among per-
sons with HIV/AIDS, even under HAART treatment.
This data prompted us to analyse HPV distribution, per-
sistence and changes in HPV multiplicity of infections
before and during antiretroviral treatment.
Materials and methods
Prevalence and persistence of mucosal HPV genotypes
and HPV16 variants were analysed in a prospective
cohort of HIV-positive and HIV-negative Italian women.
Results
HIV-positive women were more likely than HIV-nega-
tive women to be infected by HPV at the initial exami-
nation (39.3 vs 13.9%, P < 0.001) and to have a higher
period-prevalence of HPV infection over a 3-year fol-
low-up (43.8% vs 17.4%, P < 0.001), regardless of CD4+
cell counts and anti-retroviral therapy. ‘High-risk’ and
‘probable high-risk’ HPVs (types 16, 18, 31, 33, 35, 45,
52, 58 and 66), among the 20 different viral genotypes
identified, were predominant in HIV-positive (33.9%)
compared with HIV-negative (13.9%) women. Among
HIV-infected women, with normal cytology as well as
with SIL of any grade, the most common genotypes
were HPV16 followed by HPV81, -58, -72, -33 and -62.
HPV16 isolates from 18 HIV-positive and eight HIV-
negative women were classified into variant lineages
based on sequencing analysis of E6 and E7 genes and
the long control region. Whilst the HPV16 G350 Eur-
opean variant was prevalent in both HIV-positive
(10.7%) and -negative women (3.5%), HPV16 African 2
variant was only detected in HIV-positive women
(3.6%), suggesting different sexual mixing behaviours.
Discussion
The high prevalence of HPV-related lesions in our cohort
study, of HIV-positive patients under HAART-treatment,
is consistent with the reported high standardized inci-
dence rates (SIRs) of HPV-related in situ cervical (SIR
8.9, 95% CI = 8.0 to 9.9) and anal cancers (SIR 68.6, 95%
CI = 59.7 to 78.4) as well as for invasive oropharyngeal
(SIR 1.6, 95% CI = 1.2 to 2.1) and anal cancers (SIR 34.6,
95% CI = 30.8 to 38.8). The high prevalence of uncom-
mon viral genotypes and HPV16 variants in HIV-positive
women underscores the need to target a wide range of
HPV types in cervical screening of HIV-positive women.
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